SF 552: Relating to a review of anti-obesity medications by the department of health and human services and the department of administrative services for purposes of the medical assistance program and health insurance plans for state employees

What it does

This bill relates to the department of health and human services (HHS) and the department of administrative services (DAS) review of anti-obesity medication for purposes of the medical assistance program and health insurance plans for state employees established pursuant to Code chapter 509A. The bill requires HHS and DAS to review anti-obesity medications, including GLP-1 agonists, for effectiveness, comorbidities, cost savings, eligibility requirements, and short-term and long-term costs associated with coverage. HHS and DAS shall submit a report to the general assembly by January 5, 2026, containing HHS’s and DAS’s findings, proposed eligibility requirements, and any short-term and long-term costs associated with coverage.

Senate subcommittee · named February 18, 2025

• Sen. Mike Klimesh (R) · mike.klimesh@legis.iowa.gov
• Sen. Sandy Salmon (R) · sandy.salmon@legis.iowa.gov
• Sen. Zach Wahls (D) · zach.wahls@legis.iowa.gov

Lobbying · 2 for, 0 against

For: American Diabetes Association; Eli Lilly & Co.

In plain words

1. February 18, 2025Filed in the Senate and sent to the Health and Human Services committee · as SSB 1138
2. February 18, 2025Senate subcommittee named: Klimesh, Salmon and Wahls · as SSB 1138
3. February 20, 2025Subcommittee recommended passing it with changes · as SSB 1138
4. March 5, 2025Approved by the Senate committee, and given a new number: SF 552 · as SSB 1138
5. March 6, 2025Filed in the Senate
6. March 6, 2025Approved by the Senate committee
7. June 16, 2025Sent to the Senate Health and Human Services committee